Search research articles
Contact Us
Filters
Showing results (151-160 of 179) with videos related to
Page
of 18
Sort By:
Journal of Magnetic Resonance Imaging : JMRI
|
April 22, 2011
Motion correction in diffusion-weighted MRI of the breast at 3T
Lori R Arlinghaus, E Brian Welch, A Bapsi Chakravarthy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 18, 2020
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial
K Kalinsky, J R Diamond, L T Vahdat, et al.
Breast Cancer Research and Treatment
|
August 2, 2019
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer
Vandana G Abramson, Mafalda Oliveira, Andrés Cervantes, et al.
Physics in Medicine and Biology
|
August 16, 2011
A novel AIF tracking method and comparison of DCE-MRI parameters using individual and population-based AIFs in human breast cancer
Xia Li, E Brian Welch, Lori R Arlinghaus, et al.
Cancer Discovery
|
May 4, 2021
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
Otto Metzger Filho, Giuseppe Viale, Shayna Stein, et al.
The New England Journal of Medicine
|
February 21, 2019
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Ingrid A Mayer, Linda T Vahdat, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 31, 2023
Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)
Maeve A Hennessy, Jeffrey P Leal, Chiung-Yu Huang, et al.
The Oncologist
|
May 7, 2014
Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel
Douglas B Johnson, Kimberly H Dahlman, Jared Knol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2015
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer
Andres Forero-Torres, Katherine E Varley, Vandana G Abramson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2015
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019
Costanza Paoletti, Yufeng Li, Maria C Muñiz, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 179) with videos related to
Sort By:
Page
of 18
Journal of Magnetic Resonance Imaging : JMRI
|
April 22, 2011
Motion correction in diffusion-weighted MRI of the breast at 3T
Lori R Arlinghaus, E Brian Welch, A Bapsi Chakravarthy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 18, 2020
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial
K Kalinsky, J R Diamond, L T Vahdat, et al.
Breast Cancer Research and Treatment
|
August 2, 2019
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer
Vandana G Abramson, Mafalda Oliveira, Andrés Cervantes, et al.
Physics in Medicine and Biology
|
August 16, 2011
A novel AIF tracking method and comparison of DCE-MRI parameters using individual and population-based AIFs in human breast cancer
Xia Li, E Brian Welch, Lori R Arlinghaus, et al.
Cancer Discovery
|
May 4, 2021
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
Otto Metzger Filho, Giuseppe Viale, Shayna Stein, et al.
The New England Journal of Medicine
|
February 21, 2019
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Ingrid A Mayer, Linda T Vahdat, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 31, 2023
Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)
Maeve A Hennessy, Jeffrey P Leal, Chiung-Yu Huang, et al.
The Oncologist
|
May 7, 2014
Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel
Douglas B Johnson, Kimberly H Dahlman, Jared Knol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2015
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer
Andres Forero-Torres, Katherine E Varley, Vandana G Abramson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2015
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019
Costanza Paoletti, Yufeng Li, Maria C Muñiz, et al.
Page
of 18